MARKET

MESO

MESO

Mesoblast
NASDAQ
18.89
+0.60
+3.28%
Opening 10:52 12/17 EST
OPEN
18.42
PREV CLOSE
18.29
HIGH
19.18
LOW
18.42
VOLUME
121.19K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
9.61
MARKET CAP
2.42B
P/E (TTM)
-22.3365
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MESO last week (1208-1212)?
Weekly Report · 2d ago
Mesoblast Study Finds Remestemcel-L Outperforms Ruxolitinib in Treating Steroid-Refractory aGvHD
Reuters · 6d ago
INDEPENDENT STUDY PRESENTED AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING CONCLUDES REMESTEMCEL-L SUPERIOR TO RUXOLITINIB IN CLINICAL OUTCOMES AS TREATMENT FOR SR-AGVHD
Reuters · 6d ago
Bell Potter Remains a Buy on Mesoblast Limited (MEOBF)
TipRanks · 12/09 22:35
Mesoblast Limited (MEOBF) Receives a Buy from Canaccord Genuity
TipRanks · 12/08 22:35
Weekly Report: what happened at MESO last week (1201-1205)?
Weekly Report · 12/08 10:33
MESOBLAST PARTICIPATION AT PIPER SANDLER CONFERENCE
Reuters · 12/03 23:10
Weekly Report: what happened at MESO last week (1124-1128)?
Weekly Report · 12/01 10:28
More
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.